Goran Petrovski, Qatar

Sidra Medicine Pediatrics
Prof. Petrovski teaches at the Medical School in Skopje Macedonia, where he presented a treatment for 620 patients on insulin pump therapy (CSII/SAP). He started the national insulin pump program in 2002 and became chief for the Center for Insulin Pumps and Sensors in 2011, where he achieved the reimbursement of insulin pump and sensor in his country.He is a Donnell D. Etzwiler scholar at the International Diabetes Center in Minneapolis, USA and Lantus Young Investigator prize winner for clinical research in 2009 in Berlin, Germany. He’s published more than 80 papers in peer-reviewed journals and authored 4 books on type 1 diabetes, insulin pump, endocrinology test and clinical examination. He is a reviewer in multiple well-known diabetes journals (Diabetes Care, Diabetes UK, Acta Diabetologica, Diabetes Technology and Therapeutics, Journal of Technology and Science).Prof. Petrovski is a keynote speaker for international conferences on diabetes technology in Europe, Middle East, Asia & Africa and a visiting professor for several medical schools. His goal is to decrease A1c level by 1% in every uncontrolled patient with type 1 diabetes for the period of one year, until they reach satisfied glucose control.

Presenter of 4 Presentations

INDUSTRY SESSION

The 10-Days Initiation Protocol & Clinical Evidence

INDUSTRY SESSION

Practical Cases & Discussions

ORAL PRESENTATION SESSION

REMOTE INITIATION OF HYBRID CLOSED LOOP USING SKYPE IN CHILDREN AND ADOLESCENTS WITH TYPE 1 DIABETES

Abstract

Background and Aims

The aim of this study was to evaluate effectiveness of remote initiation of Hybrid Closed Loop (HCL) System on glycemic control in patients with Type 1 Diabetes (T1D) on Multiple Daily Injections (MDI).

Methods

Individuals with T1D (7 to 18 years old) initiated the MiniMed 670G HCL system using Skype Meet Now with the following program: introduction session, pre-course and technical requirements session, one face to face practical session for sensor insertion and four consecutive online sessions: Day 1- Manual Mode, bolus wizard use, basal rates, Auto Mode and readiness; Day 2- Infusion set and reservoir change; Day 3- hypoglycemia, hyperglycemia, exercise and travel management; Day 4- Evaluation to initiate HCL system. HbA1c, Time in Range, HCL system characteristics were analyzed after 3-month of HCL initiation.

Results

A total of 14, patients (age 11.4±2.8 years) and their caregivers commenced MiniMed 670G using the remote initiation program and used the system for 3 months. Sensor wear of 89.1±8.2% and Auto Mode usage of 86.8±6.8% was noted after 3 months of HCL initiation. Time in Range (70-180mg/dL) increased from 45.4±9.2% at baseline to 74.6±8.2% at the end of the study (p<0.001). There was no severe hypoglycemia nor DKA during the study.

Conclusions

Remote initiation program in individuals with T1D on MDI, can be an effective tool to initiate an HCL system and to improve glycemic control in a safe manner. Technical assessment (basic computer skills and internet connection), as well as educators’ skills on remote teaching are crucial factors in successful initiation of HCL system.

Hide
INDUSTRY SESSION

From MDI Therapy to Automated Insulin Delivery Systems : Clinical Evidence